Back to Search Start Over

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma

Authors :
Muhammad W. Saif
Iris Isufi
Jennifer Peccerillo
Kostas N. Syrigos
Source :
Gastroenterology Research and Practice, Vol 2011 (2011)
Publication Year :
2011
Publisher :
Hindawi Limited, 2011.

Abstract

Sorafenib is an oral angiogenetic multikinase inhibitor approved in the treatment of renal and hepatocellular carcinoma. Bleeding and venous thrombotic events have been described with angiogenetic agents but cerebrovascular accidents are rarely reported. We report two cases of patients with hepatocellular carcinoma who developed a cerebrovascular accident while on sorafenib. Neither patient had any risk factors for the cerebrovascular events apart from gender and age in the second patient. Laboratory data were noncontributory. The head CT scan did not reveal acute abnormalities. No hemodynamically significant stenosis was visible in the carotid ultrasound, and the echocardiogram showed normal size of the heart chambers and normal systolic function of the left ventricle. Sorafenib was discontinued in both cases. Physicians should monitor patients receiving sorafenib for neurologic symptoms, and in the absence of other etiology, prompt discontinuation of this drug should be considered.

Details

Language :
English
ISSN :
16876121 and 1687630X
Volume :
2011
Database :
Directory of Open Access Journals
Journal :
Gastroenterology Research and Practice
Publication Type :
Academic Journal
Accession number :
edsdoj.fc9044db2a4e40b3a327ce542abe9b69
Document Type :
article
Full Text :
https://doi.org/10.1155/2011/616080